TransCode Therapeutics (RNAZ) Competitors $7.94 +0.93 (+13.27%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$8.02 +0.08 (+0.94%) As of 05/21/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. DNTH, CDXC, IOVA, GHRS, ABCL, ANAB, KALV, ABUS, BCYC, and XNCRShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Dianthus Therapeutics (DNTH), ChromaDex (CDXC), Iovance Biotherapeutics (IOVA), GH Research (GHRS), AbCellera Biologics (ABCL), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), Arbutus Biopharma (ABUS), Bicycle Therapeutics (BCYC), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Dianthus Therapeutics ChromaDex Iovance Biotherapeutics GH Research AbCellera Biologics AnaptysBio KalVista Pharmaceuticals Arbutus Biopharma Bicycle Therapeutics Xencor Dianthus Therapeutics (NASDAQ:DNTH) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do insiders & institutionals believe in DNTH or RNAZ? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in DNTH or RNAZ? Dianthus Therapeutics received 12 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. Likewise, 96.55% of users gave Dianthus Therapeutics an outperform vote while only 94.12% of users gave TransCode Therapeutics an outperform vote. CompanyUnderperformOutperformDianthus TherapeuticsOutperform Votes2896.55% Underperform Votes13.45%TransCode TherapeuticsOutperform Votes1694.12% Underperform Votes15.88% Which has stronger earnings & valuation, DNTH or RNAZ? TransCode Therapeutics has lower revenue, but higher earnings than Dianthus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.52M92.43-$43.56M-$2.88-6.51TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Is DNTH or RNAZ more profitable? TransCode Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Dianthus Therapeutics' return on equity of -21.68% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,250.32% -21.68% -20.88% TransCode Therapeutics N/A -649.03%-281.34% Does the media favor DNTH or RNAZ? In the previous week, Dianthus Therapeutics had 17 more articles in the media than TransCode Therapeutics. MarketBeat recorded 18 mentions for Dianthus Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.50 beat Dianthus Therapeutics' score of 0.53 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate DNTH or RNAZ? Dianthus Therapeutics currently has a consensus target price of $53.00, indicating a potential upside of 182.67%. TransCode Therapeutics has a consensus target price of $280.00, indicating a potential upside of 3,426.45%. Given TransCode Therapeutics' higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, DNTH or RNAZ? Dianthus Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. SummaryDianthus Therapeutics beats TransCode Therapeutics on 11 of the 16 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.096.466.794.50Net Income-$18.55M$143.98M$3.23B$248.18M7 Day Performance3.79%2.03%1.53%0.20%1 Month Performance-8.79%4.11%10.06%12.37%1 Year Performance-99.98%-2.87%16.72%7.04% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.2611 of 5 stars$7.94+13.3%$280.00+3,426.4%-100.0%$6.61MN/A0.009Positive NewsEarnings ReportDNTHDianthus Therapeutics1.2697 of 5 stars$19.27-2.1%$53.00+175.0%-23.7%$619.72M$6.52M-7.7180CDXCChromaDex2.3046 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120IOVAIovance Biotherapeutics4.4368 of 5 stars$1.83+10.2%$13.30+626.8%-83.0%$611.10M$212.68M-1.23500Trending NewsGap DownGHRSGH Research2.5349 of 5 stars$11.70+6.6%$30.43+160.1%-4.6%$608.73MN/A-14.8110ABCLAbCellera Biologics2.7405 of 5 stars$2.02-0.5%$8.33+312.5%-48.3%$602.82M$23.11M-3.31500Gap UpANABAnaptysBio3.3023 of 5 stars$20.47+1.2%$35.88+75.3%-13.1%$601.41M$111.87M-3.37100Positive NewsGap DownKALVKalVista Pharmaceuticals4.3055 of 5 stars$12.07+1.2%$24.83+105.7%+2.2%$600.07MN/A-3.32100News CoveragePositive NewsABUSArbutus Biopharma1.8646 of 5 stars$3.13+1.6%$5.50+75.7%-1.2%$599.48M$6.17M-7.2890Earnings ReportGap UpBCYCBicycle Therapeutics3.7865 of 5 stars$8.63+6.5%$25.00+189.7%-62.7%$597.66M$25.72M-2.62240XNCRXencor3.7047 of 5 stars$8.06flat$29.50+266.0%-68.4%$573.64M$127.23M-2.52280 Related Companies and Tools Related Companies Dianthus Therapeutics Competitors ChromaDex Competitors Iovance Biotherapeutics Competitors GH Research Competitors AbCellera Biologics Competitors AnaptysBio Competitors KalVista Pharmaceuticals Competitors Arbutus Biopharma Competitors Bicycle Therapeutics Competitors Xencor Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
